ENDRA LIFE SCIENCES INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | $0 | $0 |
| Gross Profit | — | — | — | — | — | — | $0 | $0 |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M | $5.9M | $6.6M |
| SG&A Expense | — | $3.7M | $7.1M | $4.7M | $5.2M | $4.9M | $5.0M | $3.9M |
| Operating Income | — | $-5.8M | $-10.8M | $-10.5M | $-13.2M | $-11.5M | $-11.5M | $-10.8M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-7.0M | $-11.5M | $-10.1M | $-13.2M | $-11.2M | $-11.7M | $-13.3M |
| Income Tax Expense | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-7.0M | $-11.5M | $-10.1M | $-13.2M | $-11.2M | $-11.7M | $-13.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-8.93 | $-14.24 | — | $-0.02 | $-0.02 | $0.00 | $-0.01 |
| EPS (Diluted) | — | $-8.93 | $-14.24 | $-12.35 | — | — | $0.00 | $-0.01 |
| Shares Outstanding (Basic) | 1.2M | 787.0K | 808.4K | — | 709.9M | 476.6M | 7.63B | 1.89B |
| Shares Outstanding (Diluted) | 1.2M | 787.0K | 808.4K | 814.5K | 709.9M | 476.6M | 7.63B | 1.89B |
| Dividends Per Share | — | — | — | — | — | — | — | — |